Singapore markets closed
  • Straits Times Index

    3,095.59
    -6.62 (-0.21%)
     
  • Nikkei

    25,935.62
    -457.42 (-1.73%)
     
  • Hang Seng

    21,859.79
    -137.10 (-0.62%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • BTC-USD

    18,974.92
    -277.29 (-1.44%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • FTSE Bursa Malaysia

    1,449.74
    +5.52 (+0.38%)
     
  • Jakarta Composite Index

    6,794.33
    -117.25 (-1.70%)
     
  • PSE Index

    6,165.35
    +9.92 (+0.16%)
     

Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Coherus BioSciences, Inc. CHRS and its partner Shanghai Junshi Biosciences Co., Ltd. have announced that the FDA has granted an Orphan Drug designation to their anti-PD-1 antibody, toripalimab, for the treatment of esophageal cancer (“EC”), a rare and aggressive type of cancer.

The Orphan Drug designation is granted to drugs that are capable of treating rare diseases in the United States. This tag also entitles the company to certain other benefits and incentives to advance the development and commercialization of rare disease drugs upon potential approval.

Coherus and Junshi Biosciences are planning to submit a biologics license application supplement for toripalimab to treat EC next year.

In September 2021, the companies announced positive data from the placebo-controlled phase III JUPITER-06 study that evaluated toripalimab in combination with chemotherapy as a first-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). The study met the co-primary endpoints by demonstrating statistically significant and clinically meaningful improvements in progression-free survival and overall survival.

Shares of Coherus were up 1.6% on Monday following the announcement of the news. The stock has rallied 8.9% so far this year against the industry’s decrease of 14.2%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

We note that, apart from esophageal cancer, toripalimab is also being evaluated in late-stage studies in lung, liver, breast, kidney, bladder, stomach and skin cancers.

The BLA for toripalimab for treating advanced recurrent or metastatic nasopharyngeal carcinoma is currently under priority review in the United States with a decision from the FDA expected in April 2022.

Please note that Coherus in-licensed the rights to develop/commercialize toripalimab in the United States and Canada earlier this year from Junshi Biosciences.

Toripalimab is approved in China as Tuoyi for treating different types of cancer indications.

Zacks Rank & Stocks to Consider

Coherus currently carries a Zacks Rank #4 (Sell).

Better-ranked stocks in the biotech sector include Galera Therapeutics, Inc. GRTX, vTv Therapeutics Inc. VTVT and Editas Medicine, Inc. EDIT, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Galera Therapeutics’ loss per share estimates have narrowed 19.5% for 2021 and 32.3% for 2022, over the past 60 days.

Earnings of Galera Therapeutics have surpassed estimates in only one of the trailing four quarters, and missed the same on the other three occasions.

vTv Therapeutics’ loss per share estimates have narrowed 21.7% for 2021 and 2.9% for 2022, over the past 60 days.

vTv Therapeutics’ earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.

Editas Medicine’s loss per share estimates have narrowed 11.9% for 2021 and 4.1% for 2022, over the past 60 days.

Editas Medicine’s earnings have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Coherus BioSciences, Inc. (CHRS) : Free Stock Analysis Report

vTv Therapeutics Inc. (VTVT) : Free Stock Analysis Report

Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report

Galera Therapeutics, Inc. (GRTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting